BEAM: Beam Therapeutics Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 3 sales totaling $1.19M in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-16 | Evans John M. | CEO | $600K | yes |
| 2026-10-15 | Evans John M. | CEO | $589K | yes |
| 2026-10-01 | Cavanagh Bethany J | Officer | $5K | yes |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | 13G amendment | ARK Investment Management LLC | 9.95% | SEC | |
| 2026-08-13 | 13G amendment | Farallon Capital Management, L.L.C. | 9.99% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.